Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.084 CHF
10.67 M CHF
196.73 M CHF
140.50 M
About TG Therapeutics, Inc.
Sector
CEO
Michael Sean Weiss
Headquarters
Morrisville
Website
Founded
1993
FIGI
BBG00LVGH2Q2
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NKB2 is 28.394 CHF — it has increased by 81.57% in the past 24 hours. Watch TG THERAPEUTICS IN stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange TG THERAPEUTICS IN stocks are traded under the ticker NKB2.
NKB2 stock has risen by 81.57% compared to the previous week, the month change is a 81.57% rise, over the last year TG THERAPEUTICS IN has showed a 81.57% increase.
We've gathered analysts' opinions on TG THERAPEUTICS IN future price: according to them, NKB2 price has a max estimate of 50.05 CHF and a min estimate of 9.10 CHF. Watch NKB2 chart and read a more detailed TG THERAPEUTICS IN stock forecast: see what analysts think of TG THERAPEUTICS IN and suggest that you do with its stocks.
NKB2 reached its all-time high on Jun 25, 2021 with the price of 35.801 CHF, and its all-time low was 0 CHF and was reached on Jun 25, 2021. View more price dynamics on NKB2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NKB2 stock is 44.92% volatile and has beta coefficient of 1.40. Track TG THERAPEUTICS IN stock price on the chart and check out the list of the most volatile stocks — is TG THERAPEUTICS IN there?
Today TG THERAPEUTICS IN has the market capitalization of 3.97 B, it has decreased by −3.50% over the last week.
Yes, you can track TG THERAPEUTICS IN financials in yearly and quarterly reports right on TradingView.
TG THERAPEUTICS IN is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
NKB2 earnings for the last quarter are 0.02 CHF per share, whereas the estimation was 0.03 CHF resulting in a −33.33% surprise. The estimated earnings for the next quarter are 0.14 CHF per share. See more details about TG THERAPEUTICS IN earnings.
TG THERAPEUTICS IN revenue for the last quarter amounts to 71.08 M CHF, despite the estimated figure of 69.24 M CHF. In the next quarter, revenue is expected to reach 99.28 M CHF.
NKB2 net income for the last quarter is 3.29 M CHF, while the quarter before that showed 6.18 M CHF of net income which accounts for −46.83% change. Track more TG THERAPEUTICS IN financial stats to get the full picture.
No, NKB2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 9, 2025, the company has 264.00 employees. See our rating of the largest employees — is TG THERAPEUTICS IN on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG THERAPEUTICS IN EBITDA is −166.10 K CHF, and current EBITDA margin is 9.01%. See more stats in TG THERAPEUTICS IN financial statements.
Like other stocks, NKB2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG THERAPEUTICS IN stock right from TradingView charts — choose your broker and connect to your account.